Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria

Parassitologia

Volumn 41, Issue 1-3, 1999, Pages 409-414

  Holder, A A ^a   Guevara Patino J A ^a,b   Uthaipibull, C ^a   Syed, S E H ^a   Ling, I T ^a   Scott Finnigan, T ^a   Blackman, M J ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibody; Immune evasion; Malaria; Merozoite surface protein; Vaccine

Indexed keywords

MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PROTOZOON ANTIBODY;

ANIMAL; BIOSYNTHESIS; HUMAN; IMMUNOLOGY; PLASMODIUM FALCIPARUM; REVIEW;

ANIMALS; ANTIBODIES, PROTOZOAN; HUMANS; MALARIA VACCINES; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM;

EID: 0033182502     PISSN: 00482951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Anders RF (1986) Multiple cross-reactivities amongst antigens of Plasmodium falciparum impair the development of protective immunity against malaria. Parasite Immunol 8: 529-539.
2. Blackman MJ, Heidrich H-G, Donachie S, McBride JS, Holder AA (1990) A single fragment of a malaria merozoite surface protein remains on the parasite surface during red cell invasion and is the target of invasion-inhibiting antibodies J Exp Med 172: 379-382
3. Blackman MJ, Ling IT, Nicholls SC, Holder AA (1991) Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains Mol Biochem Parasitol 49 29-34.
4. 33 as a noncovalently associated complex with other fragments of MSP1 Mol Biochem Parasitol 50: 307-316
5. Blackman MJ, Scott-Finnigan TJ, Shai S, Holder AA (1994). Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 180: 389-393.
6. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes J Exp Med 172: 1633-1641.
7. Burghaus PA, Wellde BT, Hall T, Richards RL, Egan AF, Riley EM, Ballou WR, Holder AA (1996). Immunization of Aotus nancymai with a recombinant C-terminus of Plasmodium falciparum merozoite surface protein-1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun 64: 3614-3619.
8. Chang SP, Gibson HL, Lee-Ng CT, Barr PJ, Hui GS (1992). A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol 149: 548-555.
9. Chang SP, Case SE, Gosneil WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hui GS (1996) A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria Infect Immun 64: 253-261.
10. Daly TM, Long CA (1993). A recombinant 15-kD carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein-1 induces a protective immune response in mice Infect Immun 61: 2462-2467.
11. Daly TM, Long CA (1995) Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155: 236-243.
12. de la Cruz VF, Maloy WL, Miller LH, Lal AA, Good MF, McCutchan TF (1988). Lack of cross-reactivity between variant T cell determinants from malaria circumsporozoite protein. J Immunol 141: 2456-2460.
13. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow D, Holder AA, Riley E (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19kDa C-terminal fragment of the merozoite surface antigen, MSP-1 J Infect Dis 173 765-769.
14. Epstein N, Miller LH, Kaushel DC, Udeinya IJ, Rener J, Howard RJ, Asofsky R, Aikawa M, Hess RL (1981) Monoclonal antibodies against a specific surface determinant on malarial (Plasmodium knowlesi) merozoites block erythrocyte invasion J Immunol 127: 212-217.
15. Guevara Patiño JA, Holder AA, McBride JS, Blackman MJ (1997). Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies J Exp Med 186 1689-1699.
16. Holder AA (1988). The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy 41: 72-97
17. Holder AA (1996). Preventing merozoite invasion of erythrocytes. In: Malaria vaccine development: a multi-immune response and multi-stage perspective (Hoffman SL, ed). ASM Press, Washington, USA, pp 77-104.
18. Holder AA, Riley EM (1996). Human immune response to MSP-1. Parasitol Today 12: 173-174.
19. Kumar S, Yadava A, Keister DB, Tian JH, Ohl M, Perdue-Greenfield KA, Miller LH, Kaslow DC (1995). Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1: 325-332
20. Ling IT, Ogun SA, Holder AA (1994). Immunisation against malaria with a recombinant protein. Parasite Immunol 16 63-67.
21. Ling IT, Ogun SA, Momin P, Richards RL, Garçon N, Cohen J, Ballou WR, Holder AA (1997) Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 15: 1562-1567
22. Majarian WR, Daly TM, Weidanz WP, Long CA (1984). Passive immunization against murine malaria with IgG3 monoclonal antibody. J Immunol 132: 3131-3137.
23. Miller LH, Roberts T, Shahabuddin M, McCutchan TF (1993). Analysts of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 59: 1-14.
24. Morgan, WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus PA,.Syed SEH, Uthaipibull C, Holder AA, Feeney J (1999). Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol 289: 113-122
25. Perera KL, Handunnetti SM, Holm I, Longacre S, Mendis K (1998). Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun 66: 1500-1506.
26. Plebanski M, Lee EA, Hill AVS (1997). Immune evasion in malaria: altered peptide ligands of the orcumsporozoite protein. Parasitology 115: S55-S66.
27. Riley EM, Allen SJ, Wheeler JG, Blackman MJ, Bennett S, Takacs B, Schonfeld H-J, Holder AA, Greenwood BM (1992) Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (Pf MSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14: 321-337.
28. Saul A (1987) Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 9: 1-9.
29. Smith JD, Chitnis CE, Craig AG, Roberts DJ, Hudson-Taylor DE, Peterson DS, Pinches R, Newbold CI, Miller LH (1995) Switches in expression of Plasmodium falciparum var genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell 82: 101-110.
30. Spencer Valero LM, Ogun SA, Fleck SL, Ling IT, Scott-Finnigan TJ, Blackman, MJ Holder AA (1998) Passive immunization with antibodies against three distinct epitopes on Plasmodium yoelii merozoite surface protein-1 suppresses parasitemia. Infect Immun 66: 3925-3930
31. Stafford WHL, Blackman MJ, Harris A, Shai S, Grainger M, Holder AA (1994). N-terminal amino acid sequence of the Plasmodium falciparum merozoite surface protein-1 polypeptides Mol Biochem Parasitol 66: 157-160.
32. Tanabe K, Mackay M, Goman M, Scaife JG (1987). Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum J Mol Biol 195: 273-287.
33. Tolle R, Fruh K, Doumbo O, Koita O, Ndiaye M, Fischer A, Dietz K, Bujard H (1993). A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen -gp190 and control of malarial infections Infect Immun 61 40-47